Drug Search Results
More Filters [+]

Deslorelin

Alternative Names: deslorelin
Latest Update: 2024-08-28
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GnRH Agonist

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Topical,Nasal

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | European Medicines Agency | Ireland | Norway | Poland

Approved Indications: None

Known Adverse Events: None

Company: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Deslorelin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer|Dwarfism

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2011-00975

P2

Active, not recruiting

Breast Cancer

2024-09-15

83-CH-0199

P2

Completed

Dwarfism

None

Recent News Events